Literature DB >> 2115587

Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.

R F Brown1, M D Kinnick, J M Morin, R T Vasileff, F T Counter, E O Davidson, P W Ensminger, J A Eudaly, J S Kasher, A S Katner.   

Abstract

The preparation and biological evaluation of a series of 7 beta-[2-(2-aminothiazol-4-yl)-2(Z)-methoximinoacetamido]cep halosporins, substituted at the 3'-position with monocyclic or bicyclic nitrogen-containing heterocycles are described. The resulting family of parenteral compounds displays a broad spectrum of antibacterial activity. Some compounds exhibit a similar level of Gram-negative activity to that of the "third-generation" cephalosporins with increased staphylococcal activity. The in vitro and in vivo antimicrobial activity, structure-activity relationships, beta-lactamase stability, and in vitro and in vivo pharmacological evaluations are presented.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2115587     DOI: 10.1021/jm00170a011

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

1.  Metabolic disposition of DQ-2556, a new cephalosporin, in rats, rabbits, dogs, and monkeys.

Authors:  K Matsubayashi; S Shintani; M Yoshioka; H Tachizawa
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

2.  Structure-activity relationship of carbacephalosporins and cephalosporins: antibacterial activity and interaction with the intestinal proton-dependent dipeptide transport carrier of Caco-2 cells.

Authors:  N J Snyder; L B Tabas; D M Berry; D C Duckworth; D O Spry; A H Dantzig
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

3.  Penetration of ceftazidime into human pancreas.

Authors:  B Drewelow; K Koch; C Otto; A Franke; A K Riethling
Journal:  Infection       Date:  1993 Jul-Aug       Impact factor: 3.553

Review 4.  Cefpirome clinical pharmacokinetics.

Authors:  L C Strenkoski; D E Nix
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.